WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY

Ítems similars

• WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
  per: Jonathan Barratt, et al.
  Publicat: (2025-02-01)
• WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
  per: Jonathan Barratt, et al.
  Publicat: (2024-04-01)
• WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
  per: Jonathan Barratt, et al.
  Publicat: (2024-04-01)
• WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19
  per: Jonathan Barratt, et al.
  Publicat: (2024-04-01)
• WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
  per: Jonathan Barratt, et al.
  Publicat: (2024-04-01)